Extended Data Fig. 3. A combination of PD-L2 ablation and chemotherapy results in tumor remission.
(a) CRISPR-Cas9 genome editing of the murine Pdcd1lg2 locus, specifying the sgRNA binding site in exon 3, that generated a bulk population of edited Panc02 cells. This bulk population was used in all the experiments labelled as PD-L2-KO Panc02. (b) Quantification of tumor growth for PD-L2-WT tumors, untreated or treated with doxorubicin on days 7 and 10, including an additional group treated with anti-PD-1 depleting antibody (200 µg), or the same dose of IgG isotype control, from day 3 after tumor cell injection, twice a week. N = 6 for PBS-injected mice, n = 5 for doxo-treated, n = 7 for doxo + anti-PD-1. (c) Growth curve of WT and bulk PD-L2-KO B16-OVA tumors in C57BL/6 mice, untreated or treated with doxorubicin on days 7, 10 and 17 after subcutaneous injection of cells. B16-OVA-WT n = 5 tumors, B16-OVA-KO n = 6, B16-OVA-WT + doxo n = 11, B16-OVA-KO + doxo n = 11. 2-way ANOVA.